KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers.

Boris Kandinov, Mieke Soens, Wenmei Huang, Conrado Llapur, David Ensz, Brandon Essink, Carlos Fierro, Jignesh Vakil, Alicia Pucci, Jia Guo, Sinead Rudden, Kristi Hall, Bryony Hicks, Kristin Schaefers, Honghong Zhou, Chong Ma, Lingyi Zheng, Andrei Avanesov, Yoonyoung Park, Evelyn Du, Jacqueline Miller, Jintanat Ananworanich, Raffael Nachbagauer

Hum Vaccin Immunother 21(1) 2484088

PMID40174609
PMCIDPMC11970786
DOI10.1080/21645515.2025.2484088
发表日期2025-04-02
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 flow diagram;Figure 2.:非 KM 图;Figure 3.:ROC 图;Figure 4.:非 KM 图;Figure 5.:非 KM 图。
摘要

摘要

The safety, immunogenicity, and efficacy of the original formulation of the investigational mRNA-1010 vaccine for seasonal influenza were investigated in two randomized, active-controlled, phase 3 trials in adults (NCT05415462 and NCT05566639), and the results were used to evaluate hemagglutination inhibition (HAI) titers as correlates of risk and protection against influenza-like illness. mRNA-1010 (50-µg) demonstrated an acceptable reactogenicity and safety profile among the >14,000 adult participants vaccinated in both trials. The efficacy profile of mRNA-1010 was generally reflective of immunogenicity findings, with higher immune responses against influenza A strains and lower responses against influenza B strains relative to an active comparator (licensed inactivated influenza vaccine). An analysis of HAI titers as a correlate of protection against influenza infection provided support for its use as a surrogate endpoint for mRNA-1010, similar to licensed influenza vaccines. These findings support further optimization and development of mRNA-1010 against seasonal influenza.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Participant disposition for the P301 and P302 studies.
非 KM Figure
Figure 2.Participants with local and systemic adverse reactions within seven days after vaccination in the P301 study (a) and the P302 study (b) by grade, vaccine, and age group (solicited safety population).
非 KM Figure
Figure 3.Geometric mean titer ratio (a) and seroconversion rate difference (b) of anti-hemagglutinin antibodies against influenza strains A/H1N1, A/H3N2, B/Victoria, and B/Yamagata for mRNA-1010 vs active comparator at Day 29 in the P301 study (per-protocol immunogenicity population).
非 KM Figure
Figure 4.Multivariate analysis of Day 29 HAI titers for predicting influenza infections in the P301 study.
非 KM Figure
Figure 5.Influenza infection risk by Day 29 HAI titer for each strain in the P301 study.
非 KM Figure